Cargando…
Bronchial artery embolization for the management of frequent hemoptysis caused by bronchiectasis
BACKGROUND: To retrospectively evaluate the effectiveness of bronchial artery embolization (BAE) compared with conservative therapy for the treatment of frequent hemoptysis caused by bronchiectasis. METHODS: From January 2015 to December 2019, consecutive patients who were admitted due to frequent (...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9624090/ https://www.ncbi.nlm.nih.gov/pubmed/36319977 http://dx.doi.org/10.1186/s12890-022-02198-2 |
_version_ | 1784822157227851776 |
---|---|
author | Lu, Guang-Dong Yan, Hai-Tao Zhang, Jin-Xing Liu, Sheng Shi, Hai-Bin Zu, Qing-Quan |
author_facet | Lu, Guang-Dong Yan, Hai-Tao Zhang, Jin-Xing Liu, Sheng Shi, Hai-Bin Zu, Qing-Quan |
author_sort | Lu, Guang-Dong |
collection | PubMed |
description | BACKGROUND: To retrospectively evaluate the effectiveness of bronchial artery embolization (BAE) compared with conservative therapy for the treatment of frequent hemoptysis caused by bronchiectasis. METHODS: From January 2015 to December 2019, consecutive patients who were admitted due to frequent (more than three times per year) bronchiectasis-related hemoptysis were retrospectively reviewed. Those who were treated with either BAE (n = 69) or conservative therapy (n = 47) were enrolled for analysis. The technical success, clinical success, and complications of the BAE procedure were evaluated. Long-term hemoptysis-free survival rates and clinical success were compared between patients in the BAE group and patients in the conservative group. A Cox proportional hazard regression model was used to identify the predictors of recurrent hemoptysis. RESULTS: The technical success rate was 100% for the BAE procedure, and clinical success was achieved in 92.8% (64 of 69) of cases. No major procedure-related complications occurred, and minor complications were observed in 16 cases (23.2%). The 1-, 2-, and 3-year hemoptysis-free survival rates were 88.3, 71.3, and 66.2%, respectively, for the BAE group and 31.9, 17.6, and 2.5%, respectively, for the conservative treatment group (P < 0.001). Multivariate analysis showed that BAE was a protective factor against recurrent hemoptysis in treated patients. In addition, the presence of cystic bronchiectasis was the only independent risk factor for rebleeding in the whole population and in the BAE group. CONCLUSIONS: BAE may provide an effective option for patients with frequent bronchiectasis-related hemoptysis, especially for those without cystic bronchiectasis. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12890-022-02198-2. |
format | Online Article Text |
id | pubmed-9624090 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-96240902022-11-02 Bronchial artery embolization for the management of frequent hemoptysis caused by bronchiectasis Lu, Guang-Dong Yan, Hai-Tao Zhang, Jin-Xing Liu, Sheng Shi, Hai-Bin Zu, Qing-Quan BMC Pulm Med Research BACKGROUND: To retrospectively evaluate the effectiveness of bronchial artery embolization (BAE) compared with conservative therapy for the treatment of frequent hemoptysis caused by bronchiectasis. METHODS: From January 2015 to December 2019, consecutive patients who were admitted due to frequent (more than three times per year) bronchiectasis-related hemoptysis were retrospectively reviewed. Those who were treated with either BAE (n = 69) or conservative therapy (n = 47) were enrolled for analysis. The technical success, clinical success, and complications of the BAE procedure were evaluated. Long-term hemoptysis-free survival rates and clinical success were compared between patients in the BAE group and patients in the conservative group. A Cox proportional hazard regression model was used to identify the predictors of recurrent hemoptysis. RESULTS: The technical success rate was 100% for the BAE procedure, and clinical success was achieved in 92.8% (64 of 69) of cases. No major procedure-related complications occurred, and minor complications were observed in 16 cases (23.2%). The 1-, 2-, and 3-year hemoptysis-free survival rates were 88.3, 71.3, and 66.2%, respectively, for the BAE group and 31.9, 17.6, and 2.5%, respectively, for the conservative treatment group (P < 0.001). Multivariate analysis showed that BAE was a protective factor against recurrent hemoptysis in treated patients. In addition, the presence of cystic bronchiectasis was the only independent risk factor for rebleeding in the whole population and in the BAE group. CONCLUSIONS: BAE may provide an effective option for patients with frequent bronchiectasis-related hemoptysis, especially for those without cystic bronchiectasis. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12890-022-02198-2. BioMed Central 2022-11-01 /pmc/articles/PMC9624090/ /pubmed/36319977 http://dx.doi.org/10.1186/s12890-022-02198-2 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Lu, Guang-Dong Yan, Hai-Tao Zhang, Jin-Xing Liu, Sheng Shi, Hai-Bin Zu, Qing-Quan Bronchial artery embolization for the management of frequent hemoptysis caused by bronchiectasis |
title | Bronchial artery embolization for the management of frequent hemoptysis caused by bronchiectasis |
title_full | Bronchial artery embolization for the management of frequent hemoptysis caused by bronchiectasis |
title_fullStr | Bronchial artery embolization for the management of frequent hemoptysis caused by bronchiectasis |
title_full_unstemmed | Bronchial artery embolization for the management of frequent hemoptysis caused by bronchiectasis |
title_short | Bronchial artery embolization for the management of frequent hemoptysis caused by bronchiectasis |
title_sort | bronchial artery embolization for the management of frequent hemoptysis caused by bronchiectasis |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9624090/ https://www.ncbi.nlm.nih.gov/pubmed/36319977 http://dx.doi.org/10.1186/s12890-022-02198-2 |
work_keys_str_mv | AT luguangdong bronchialarteryembolizationforthemanagementoffrequenthemoptysiscausedbybronchiectasis AT yanhaitao bronchialarteryembolizationforthemanagementoffrequenthemoptysiscausedbybronchiectasis AT zhangjinxing bronchialarteryembolizationforthemanagementoffrequenthemoptysiscausedbybronchiectasis AT liusheng bronchialarteryembolizationforthemanagementoffrequenthemoptysiscausedbybronchiectasis AT shihaibin bronchialarteryembolizationforthemanagementoffrequenthemoptysiscausedbybronchiectasis AT zuqingquan bronchialarteryembolizationforthemanagementoffrequenthemoptysiscausedbybronchiectasis |